Angioimmunoblastic T-Cell Lymphoma: Treatment Options

Angioimmunoblastic
T-Cell Lymphoma

Treatment Options

Patients with AITL may be treated with a steroid that can temporarily relieve the symptoms caused by the immune system’s reaction to the cancer cells, such as joint inflammation or pain and skin rash.

Recommended first-line therapy is either a clinical trial or a multiagent chemotherapy regimen, such as CHOP (cyclophosphamide doxorubicin, vincristine, and prednisone). Sometimes higher doses of chemotherapy followed by stem cell transplantation may be added to multiagent chemotherapy.

Several drugs have been tested in small clinical trials (alone or in combination with current chemotherapy regimens) and show promise for the treatment of AITL, including:

  • Brentuximab vedotin (Adcetris)
  • Lenalidomide (Revlimid)
  • Panobinostat (Farydak)

Learn More

To learn more about AITL, view the T-Cell Lymphomas Guide. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].

Additional Resources

To learn more about AITL, view the T-Cell Lymphomas Guide.

Events